PETVIVO HOLDINGS, INC. TO EXHIBIT AT THE IVAPM PAIN MANAGEMENT FORUM IN ATLANTA, GEORGIA
March 27 2023 - 8:00AM
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) ("PetVivo") an
emerging biomedical device company focused on the commercialization
of innovative medical therapeutics for pets announced today it is a
Platinum Sponsor and will be exhibiting at the International
Veterinary Academy of Pain Management (“IVAPM”) Pain Management
Forum to be held April 2nd to April 4th 2023 at the Westin
Peachtree Plaza in Atlanta, Georgia.
PetVivo intends to exhibit its lead product,
SPRYNG™ with OsteoCushion™ Technology, an intra-articular
injectable veterinary medical device consisting of sterilized,
extra-cellular matrix microparticles; Spryng microparticles perform
in the joint as wet, slippery micro-cushions used in the management
of lameness and other joint related afflictions, such as
osteoarthritis.
“The IVAPM Pain Management Forum provides us an
excellent event to demonstrate to leading pain management experts
in the veterinary profession our innovative medical device for the
management of osteoarthritis, Spryng, with OsteoCushion Technology”
said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
“We welcome the opportunity to support the IVAPM and participate in
this forum to explain the benefits of Spryng and how it may be used
to enhance the lives of companion animals.”
For more information about PetVivo Holdings,
Inc. please contact info1@petvivo.com or visit
https://petvivo.com/
Conference Details:
Pain Management Forum Exhibit Details:
International Veterinary Academy of Pain
Management (“IVAPM”)
Booth #: 4&5
Dates:
Sunday, April 2, 2023 9:00am – 7:30pm
Monday, April 3, 2023 9:00am – 7:30pm
Tuesday, April 4, 2023 9:00am – 4:00pm
Location: The Westin Peachtree Plaza in Atlanta,
Georgia
About PetVivo Holdings,
Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW)
is an emerging biomedical device company currently focused on the
manufacturing, commercialization and licensing of innovative
medical devices and therapeutics for companion animals. The
Company's strategy is to leverage human therapies for the treatment
of companion animals in a capital and time efficient way. A key
component of this strategy is the accelerated timeline to revenues
for veterinary medical devices, which enter the market much earlier
than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for
the treatment of animals and people. A portfolio of nineteen
patents protects the Company's biomaterials, products, production
processes and methods of use. The Company’s lead product SPRYNG™
with OsteoCushion™ technology, a veterinarian-administered,
intraarticular injectable medical device for the management of
lameness and other joint related afflictions, including
osteoarthritis, in dogs and horses, is currently available for
commercial sale.
For more information about PetVivo Holdings,
Inc. and our revolutionary product, Spryng with OsteoCushion
Technology, please contact info1@petvivo.com or visit
https://petvivo.com/.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking Statements:
The foregoing material may contain
“forward-looking statements” within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, each as amended. Forward-looking statements
include all statements that do not relate solely to historical or
current facts, including without limitation the Company’s proposed
development and commercial timelines, and can be identified by the
use of words such as “may,” “will,” “expect,” “project,”
“estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,”
“continue” or the negative versions of those words or other
comparable words. Forward-looking statements are not guarantees of
future actions or performance. These forward-looking statements are
based on information currently available to the Company and its
current plans or expectations and are subject to a number of
uncertainties and risks that could significantly affect current
plans. Risks concerning the Company’s business are described in
detail in the Company’s Annual Report on Form 10-K for the year
ended March 31, 2022 and other periodic and current reports filed
with the Securities and Exchange Commission. The Company is under
no obligation to, and expressly disclaims any such obligation to,
update or alter its forward-looking statements, whether as a result
of new information, future events or otherwise.
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jun 2024 to Jul 2024
PetVivo (NASDAQ:PETV)
Historical Stock Chart
From Jul 2023 to Jul 2024